FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000322406> ?p ?o ?g. }

• W2000322406 endingPage "977" @default.
• W2000322406 startingPage "967" @default.
• W2000322406 abstract "The Journal of Clinical PharmacologyVolume 40, Issue 9 p. 967-977 An Overview of Antihypertensive Therapy in the 20th Century Robert W. Piepho PhD, FCP, Robert W. Piepho PhD, FCP School of Pharmacy, University of Missouri—Kansas City, Kansas City, Missouri.Search for more papers by this authorJessica Beal PharmD, Jessica Beal PharmD School of Pharmacy, University of Missouri—Kansas City, Kansas City, Missouri.Search for more papers by this author Robert W. Piepho PhD, FCP, Robert W. Piepho PhD, FCP School of Pharmacy, University of Missouri—Kansas City, Kansas City, Missouri.Search for more papers by this authorJessica Beal PharmD, Jessica Beal PharmD School of Pharmacy, University of Missouri—Kansas City, Kansas City, Missouri.Search for more papers by this author First published: 08 March 2013 https://doi.org/10.1177/00912700022009693Citations: 10 Dean, School of Pharmacy, University of Missouri—Kansas City, 5100 Rockhill Road, Kansas City, MO 64110. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Riva-Rocci S: Un nuovo sfigmomanometro. Gazetta medica di Torino 1896; 47: 981– 996;1001–1017. English translation: Faulconer A Jr, Keys TE (eds.): Foundations of Anesthesiology. Vol. 2. Springfield, IL: Charles C Thomas, 1965;1043-1075. 2 Oliver G, Schafer EA: The physiological effects of extracts from the suprarenal capsules. J Physiol (Lond) 1895; 18: 230– 276. 3 Abel JJ: On epinephrine, the active constituent of the suprarenal capsule and its compounds. Proc Am Physiol Soc (Bost) 1898; 3. 4 Tigerstedt R, Bergman PG: Niere and Kreislauf. Skand Arch Physiol 1898; 8: 223. 5 National Center for Health Statistics: Vital Statistics of the United States, 1990-1995: Vol. 2. Mortality. Part A. Washington, DC: Government Printing Office, 19901995. 6 Korotkoff NS: On methods of studying blood pressure. Izv Akad Nauk SSSR (Biol) 1905; 11: 365. 7 Elliott TR: On the action of adrenalin. Proc Physiol Soc (Lond) 1904; 29: 20. 8 Esunge PM: From blood pressure to hypertension: the history of research. J R Soc Med 1991; 84: 621. 9 Janeway TC: A clinical study of hypertensive cardiovascular disease. Arch Intern Med 1913; 12: 755– 798. 10 Barger G, Dale HH: Chemical structure and sympathomimetic action of amines. J Physiol (Lond) 1910; 41: 19– 59. 11 Dale HH: On some physiological actions of ergot. J Physiol 1906; 34: 163– 206. 12 Barger G, Dale HH: The presence in ergot and physiological activity of B-imidazolethylamine. Proc Physiol Soc (Lond) 1910; 38– 40. 13 Rowntree LG, Adson AW: Bilateral lumbar sympathetic neurectomy in the treatment of malignant hypertension. JAMA 1925; 85: 959– 961. 14 Adson AW, Brown GE: Malignant hypertension: report of case treated by bilateral section of anterior spinal nerve roots from the sixth thoracic to the second lumbar, inclusive. JAMA 1934; 102: 1115– 1118. 15 Comroe JH Jr: First annual Irvine H. Page lecture. Cleveland Clinic Quarterly 1978; 45(4): 311– 323. 16 Goldblatt H: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59: 347. 17 Page IH: The effect on renal efficiency of lowering arterial blood pressure in cases of essential hypertension and nephritis. J Clin Invest 1934; 13: 909– 915. 18 Page IH, Heuer GJ: A surgical treatment of essential hypertension. J Clin Invest 1935; 14: 22– 26. 19 Cannon WB, Rosenblueth A: Transmission of impulses through sympathetic ganglion. Am J Physiol 1937; 119: 221– 235. 20 Keith NM, Wagener HP, Barker NW: Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197: 332– 343. 21 Vertes V, Tobias L, Galvin S: Historical reflections on hypertension. Prim Care 1991; 18(3): 471– 482. 22 Dustan HP: Hypertension revisited after 55 years: how it has changed! Am J Med Sci 1995; 309(2): 69– 70. 23 Page IH, Helmer OM: A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med 1940; 71: 29– 42. 24 Braun-Menendez E, Fasciolo JC, Leloir CF, et al: The substance causing renal hypertension. J Physiol (Lond) 1940; 98: 283. 25 von Euler US: Presence of sympathomimetic substance in extracts of mammalian heart. J Physiol 1946; 105: 38– 44. 26 Ahlquist RP: A study of the adrenotropic receptors. Am J Physiol 1948; 153: 586– 600. 27 Rapport MM, Green AA, Page IH: Crystalline serotonin. Science 1948; 108: 329– 330. 28 Barach AL: Franklin Roosevelt's illness: effect on course of history. New York State Journal of Medicine 1977; 77(13): 2154– 2157. 29 Moser M: Evolution of the treatment of hypertension from the 1940s to JNC V. Am J Hypertens 1997; 10: 2S– 8S. 30 Freis ED, Wilkins RW: Effect of pentaquine in patients with hypertension. Proc Soc Exp Biol Med 1947; 64: 731– 736. 31 Krayer O, Acheson GH: The pharmacology of the veratrum alkaloids. Physiol Rev 1946; 26: 383– 446. 32 Vakil RJ: A clinical trial of rauwolfia serpentina in essential hypertension. Br Heart J 1949; 11: 350– 355. 33 Reubi F: The influence of some peripheral vasodilators on the renal circulation. Helv Med Acta 1949; 16: 297. 34 Smirk FH: Action of a new methonium compound in arterial hypertension. Lancet 1953; 1: 457– 464. 35 Simpson FO, Hodge JV: The evolution of antihypertensive therapy. N Z Med J 1968; 67: 270– 275. 36 Powell CE, Slater IH: Some aspects of blockade of inhibitory adrenergic receptors by a dichloro analogue of isoproterenol. J Pharmacol Exp Ther 1958; 122: 480– 488. 37 Freis ED, Wanko A, Wilson IM, Parrish AE: Treatment of hypertension with chlorothiazide (Diuril). JAMA 1958; 166: 137. 38 Bumpus FM, Schwarz H, Page IH: Synthesis andpharmacology of the octapeptide angiotonin. Science 1957; 125: 886– 887. 39 Page IH: The renin angiotensin pressor system, in: ET Bell (ed.), Hypertension. Minneapolis: Minnesota University Press, 1957; 66. 40 Prichard BNC: Hypotensive action of pronethalol. Br Med J 1964; 1: 1227– 1228. 41 Prichard BNC, Gillam PMS: The use of propranolol in the treatment of hypertension. Br Med J 1964; 2: 725– 727. 42 Fleckenstein A: Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions, in: P Harris, L Opie (eds.), Calcium and the Heart. London: Academic Press, 1971; 135. 43 Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity and mortality: I. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 1970; 202: 1028. 44 Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143– 1152. 45 National High Blood Pressure Education Program, Task Force I: Report to the Hypertension Information and Education Advisory Committee. Recommendations for a national high blood pressure data base for effective antihypertensive therapy. U.S. Department of Health, Education and Welfare Publication No. (NIH) 74-593. Washington, DC: Government Printing Office, 1973. 46 Bühler HR, Laragh JH, Baer L, et al: Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 187: 1209– 1214. 47 Brunner HR, Gavras H, Laragh JH, et al: Hypertension in man: exposure of the renin and sodium components using angiotensin II blockade. Circ Res 1974; 34(Suppl. 1): 35– 43. 48 Streeten DHP, Anderson GH Jr, Dalakos TG: Angiotensin blockade: its clinical significance. Am J Med 1976; 60: 817– 824. 49 Case DB, Wallace JM, Keim JH, et al: Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. Am J Med 1976; 61: 790– 796. 50 Case DB, Wallace JM, Laragh JH: Comparison between saralasin and converting enzyme inhibitor in hypertensive disease. Kidney Int 1979; 15(Suppl. 9): S107– S114. 51 Gavras H, Brunner HR, Turini GA, et al: Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 28: 991– 995. 52 Kannel WB: Hypertension in Framingham, in: O Paul (ed.): Epidemiology and Control of Hypertension. New York: McGraw-Hill, 1975; 553– 592. 53 Smith WM: Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res 1977; 40(Suppl. 1): 198. 54 Hypertension Detection and Follow-Up Program Cooperative: Five-year findings of the Hypertension Detection and Follow-up Program. JAMA 1979; 242: 2562. 55 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC I). JAMA 1977; 237: 255– 261. 56 Helgeland A: Treatment of mild hypertension: a five-year controlled drug trial. The Oslo Study. Am J Med 1980; 69: 725. 57 The Australian therapeutic trial in mild hypertension: report by the Management Committee. Lancet 1980; 1: 1261. 58 Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97. 59 Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 248: 1465. 60 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980; 140: 1280– 1285. 61 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984; 144: 1045– 1057. 62 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023– 1038. 63 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154– 183. 64 Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338(8778): 1281– 1285. 65 Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 69– 77. 66 Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875): 821– 828. 67 Kober L, Torp-Pedersen C, Carlsen JE, et al: A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333(25): 1670– 1676. 68 Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20): 1456– 1462. 69 Psaty B, Heckbert S, Koepsell T: The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620– 625. 70 The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157(21): 2413– 2446. 71 Hansson L, Lindholm LH, Ekbom T, et al: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999; 354(9192): 1751– 1756. 72 Davis BR, Cutler JA, Gordon DJ, et al: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1997; 10(1): 142– 143. 73 The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145– 153. 74 Weber M: Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999; 12: 139S– 147S. 75 USP DI: Approved Drug Products and Legal Requirements. 20th ed., vol. 3. Englewood, CO: Micromedex, 2000. 76 SK Hebel, TH Bernham (eds.): Drug Facts and Comparisons. St. Louis, MO: Facts and Comparisons, Inc., 1998. Citing Literature Volume40, Issue9September 2000Pages 967-977 ReferencesRelatedInformation" @default.
• W2000322406 created "2016-06-24" @default.
• W2000322406 creator A5034823291 @default.
• W2000322406 creator A5047411939 @default.
• W2000322406 date "2000-09-01" @default.
• W2000322406 modified "2023-10-16" @default.
• W2000322406 title "An Overview of Antihypertensive Therapy in the 20th Century" @default.
• W2000322406 cites W1490285206 @default.
• W2000322406 cites W180946569 @default.
• W2000322406 cites W1963559625 @default.
• W2000322406 cites W1972316794 @default.
• W2000322406 cites W1981418296 @default.
• W2000322406 cites W1990056663 @default.
• W2000322406 cites W1997388963 @default.
• W2000322406 cites W2004095675 @default.
• W2000322406 cites W2005998322 @default.
• W2000322406 cites W2008810573 @default.
• W2000322406 cites W2015163526 @default.
• W2000322406 cites W2020325809 @default.
• W2000322406 cites W2029118885 @default.
• W2000322406 cites W2032414191 @default.
• W2000322406 cites W2036373689 @default.
• W2000322406 cites W2052624720 @default.
• W2000322406 cites W2054578139 @default.
• W2000322406 cites W2054830441 @default.
• W2000322406 cites W2057957041 @default.
• W2000322406 cites W2064327398 @default.
• W2000322406 cites W2080040416 @default.
• W2000322406 cites W2082281095 @default.
• W2000322406 cites W2090555756 @default.
• W2000322406 cites W2091529445 @default.
• W2000322406 cites W2106073810 @default.
• W2000322406 cites W2119369921 @default.
• W2000322406 cites W2121833804 @default.
• W2000322406 cites W2128221835 @default.
• W2000322406 cites W2130559826 @default.
• W2000322406 cites W2131120290 @default.
• W2000322406 cites W2139805666 @default.
• W2000322406 cites W2140909944 @default.
• W2000322406 cites W2158415162 @default.
• W2000322406 cites W2281938476 @default.
• W2000322406 cites W2312388685 @default.
• W2000322406 cites W2316814104 @default.
• W2000322406 cites W2318431042 @default.
• W2000322406 cites W2321342842 @default.
• W2000322406 cites W2326354230 @default.
• W2000322406 cites W2408524794 @default.
• W2000322406 cites W2435772150 @default.
• W2000322406 cites W2565152406 @default.
• W2000322406 cites W2615684303 @default.
• W2000322406 cites W3022929210 @default.
• W2000322406 cites W4232706911 @default.
• W2000322406 cites W4242459468 @default.
• W2000322406 cites W4243843346 @default.
• W2000322406 cites W4244918166 @default.
• W2000322406 cites W4246121474 @default.
• W2000322406 cites W4255533584 @default.
• W2000322406 cites W4255594164 @default.
• W2000322406 cites W4255974390 @default.
• W2000322406 cites W4294916050 @default.
• W2000322406 doi "https://doi.org/10.1177/00912700022009693" @default.
• W2000322406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10975068" @default.
• W2000322406 hasPublicationYear "2000" @default.
• W2000322406 type Work @default.
• W2000322406 sameAs 2000322406 @default.
• W2000322406 citedByCount "21" @default.
• W2000322406 countsByYear W20003224062012 @default.
• W2000322406 countsByYear W20003224062014 @default.
• W2000322406 countsByYear W20003224062016 @default.
• W2000322406 countsByYear W20003224062017 @default.
• W2000322406 countsByYear W20003224062018 @default.
• W2000322406 countsByYear W20003224062019 @default.
• W2000322406 countsByYear W20003224062020 @default.
• W2000322406 countsByYear W20003224062023 @default.
• W2000322406 crossrefType "journal-article" @default.
• W2000322406 hasAuthorship W2000322406A5034823291 @default.
• W2000322406 hasAuthorship W2000322406A5047411939 @default.
• W2000322406 hasConcept C126322002 @default.
• W2000322406 hasConcept C177713679 @default.
• W2000322406 hasConcept C71924100 @default.
• W2000322406 hasConcept C98274493 @default.
• W2000322406 hasConceptScore W2000322406C126322002 @default.
• W2000322406 hasConceptScore W2000322406C177713679 @default.
• W2000322406 hasConceptScore W2000322406C71924100 @default.
• W2000322406 hasConceptScore W2000322406C98274493 @default.
• W2000322406 hasIssue "9" @default.
• W2000322406 hasLocation W20003224061 @default.
• W2000322406 hasLocation W20003224062 @default.
• W2000322406 hasOpenAccess W2000322406 @default.
• W2000322406 hasPrimaryLocation W20003224061 @default.
• W2000322406 hasRelatedWork W1506200166 @default.
• W2000322406 hasRelatedWork W1995515455 @default.
• W2000322406 hasRelatedWork W2048182022 @default.
• W2000322406 hasRelatedWork W2080531066 @default.
• W2000322406 hasRelatedWork W2604872355 @default.
• W2000322406 hasRelatedWork W2748952813 @default.
• W2000322406 hasRelatedWork W2899084033 @default.
• W2000322406 hasRelatedWork W3031052312 @default.

• next